Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

As the last of the Baby Boomer generation has turned 60, recalibrating retirement nest eggs towards more income will be ...

KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Value outperformed in 2022, with the Russell 1000 Value index falling about 7.5 percent compared to a more than 29 percent ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Vanguard Mid-Cap Value ETF features solid sector diversification. Learn why VOE's stock ranking and cash-flow valuation ...

The S&P 500’s construction lends itself well to full replication: copying an index’s holdings and weightings exactly.

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...